Shares fell 4.5% after the earnings release as investors reacted negatively to cautious ELEVIDYS growth commentary and a reiterated full-year guidance range that lacked upward revision amid ongoing commercial ramp challenges.

• Total net product revenue reached $331 million, including $229 million from PMO therapies and $102 million from ELEVIDYS.
• Management emphasized stabilization of marketed products but highlighted the gradual path from patient consideration to infusion for ELEVIDYS.
• Full-year ELEVIDYS revenue guidance was reiterated at $1.2 billion to $1.4 billion, signaling no acceleration despite evidence of clinical benefit.
• Financial position remains solid, with approximately $748 million in cash and investments and positive GAAP and non-GAAP earnings.
• Pipeline progress continues, especially with siRNA programs in DM1, FSHD, and Huntington’s disease, although meaningful impacts remain on the horizon.